FLASCO

Announcing a New Indication for a PERJETA

  • FLASCO
  • January 8, 2018

Genentech is excited to share the news of the FDA approval of PERJETA in combination with trastuzumab and chemotherapy as:

·       Neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer

·       Adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence

The FDA approval letter for PERJETA can be found at

 https://www.genentech-access.com/PERJETA

 

Genentech Access Solutions offers a range of access and reimbursement support to help patients begin treatment as soon as possible. We can help your patients by providing:

·       Full benefits investigations

·       Prior authorization resources

·       Sample billing and coding information

·       Resources for appeals

·       Patient assistance options

For more information about PERJETA Access Solutions, please contact me directly, visit https://www.genentech-access.com/hcp/brands/perjeta.html or call 1-888-249-4918, Monday
through Friday, 6
AM–5 PM PT

Who’s Online

There are no users currently online